The Lede

One Vaccine-Schedule Change That Actually Makes Sense

一项真正合理的疫苗接种计划调整
Amid R.F.K., Jr.,’s vandalism of the public-health system, there’s shocking good news about a cancer-preventing vaccine.
在小罗伯特·F·肯尼迪破坏公共卫生体系之际,一种预防癌症的疫苗传来了惊人的好消息。
woman body vaccine explosion dots
Illustration by Shawna X

On January 5th, the Department of Health and Human Services, under the direction of Robert F. Kennedy, Jr., removed several vaccines from the universally recommended schedule for children: hepatitis A and B, meningococcal disease, rotavirus, influenza, and respiratory syncytial virus. These changes came after the removal, about seven months earlier, of the COVID vaccine. It’s become nearly impossible to find additional words to describe the vandalism of the American public-health system. In a statement, Andrew Racine, the president of the American Academy of Pediatrics, tried: “For decades, leading health experts, immunologists, and pediatricians have carefully reviewed new data and evidence as part of the immunization recommendation process, helping to keep newborns, infants, and children protected from diseases they could be exposed to in the United States as they develop and grow. Today’s decision, which was based on a brief review of other countries’ practices, upends this deliberate scientific process.” In the past thirty years or so, routine childhood vaccinations in the United States have prevented the deaths of an estimated 1.1 million children, and precluded thirty-two million hospitalizations.

1月5日,在罗伯特·F·肯尼迪的领导下,美国卫生与公众服务部将甲肝、乙肝、脑膜炎、轮状病毒、流感和呼吸道合胞病毒疫苗从儿童常规推荐接种清单中移除。此前约七个月,新冠疫苗已被移出清单。美国公共卫生体系遭到的破坏,几乎已找不到更多词语来形容。美国儿科学会主席安德鲁·拉辛在一份声明中尝试这样描述:“几十年来,顶尖健康专家、免疫学家和儿科医生作为免疫推荐流程的一部分,仔细审查新的数据和证据,帮助新生儿、婴儿和儿童在成长过程中免受美国境内可能接触到的疾病侵害。今天的决定基于对其他国家的做法进行的简短审查,颠覆了这一严谨的科学流程。”过去三十年间,美国的常规儿童疫苗接种估计已防止110万儿童死亡,避免了3200万人次住院。

But there is some good news. The new vaccine schedule contains one sensible and significant change. The human-papillomavirus (H.P.V.) vaccine, which protects against cervical cancer, was previously given as a series of two or three vaccinations; now it will be just one. The move might at first sound like little more than a reduced hassle—and maybe reckless, since there was good evidence in support of the three-shot regimen—but outside the U.S., in nineteen countries that switched to a one-dose regimen, the change led to some 18.5 million additional girls being vaccinated, averting an estimated three hundred thousand cases of cervical cancer. The hastiness with which H.H.S. revised the vaccine schedule suggests that the H.P.V. dosing shift came about almost incidentally, a side effect of a program of hacking away at vaccines generally. If so, there’s something fitting there. The realization that a single H.P.V. dose would work was itself, in large part, a felicitous by-product of the troubles that vaccine-research projects often encounter. Even the development of the H.P.V. vaccine involved some luck.

不过,也有好消息。新的疫苗接种计划包含了一项合理且重要的调整。预防宫颈癌的人乳头瘤病毒(H.P.V.)疫苗,原本需要接种两到三剂,现在只需一剂。乍一看,这一变化似乎只是减少了麻烦——甚至可能有些鲁莽,因为此前有充分证据支持三剂接种方案——但在美国以外的19个已改用单剂接种方案的国家,这一调整使约1850万女孩额外接种了疫苗,估计避免了30万例宫颈癌的发生。美国卫生与公众服务部仓促修订疫苗接种计划的做法表明,H.P.V.疫苗剂量的调整几乎是偶然发生的,更像是整体削减疫苗计划的一个副产品。如果是这样,倒也恰如其分。单剂H.P.V.疫苗有效的发现,在很大程度上本身就是疫苗研究项目常遇困境带来的意外收获。甚至H.P.V.疫苗的研发过程也包含了一些运气成分。

A mythical mischief-maker, the jackalope is a rabbit-like creature with antelope-like horns. In some tales, it has a gift for mimicking human voices. But not every horned rabbit is make-believe. In 1931, Richard Shope, a researcher at the Rockefeller Institute, noticed a tumor on the foot of a rabbit he had shot near Princeton, New Jersey; soon afterward, he began collecting and studying similar tumors on other wild rabbits. One day, the father of an administrator in Shope’s lab, visiting from Cherokee, Iowa, said that these growths were nothing compared with what he saw back home. “He said he had shot rabbits with horns out of the side of their heads like Texas steers, or out of the top of their noses like rhinoceroses,” Shope wrote, in unpublished notes. Shope went out to Iowa with the Iowan for a few days, to hunt for horned cottontail rabbits; before returning, he left five dollars and a bottle of glycerol, saying that he’d pay another five for any horns mailed to him.

神话中的恶作剧制造者——鹿角兔,是一种形似兔子、长着羚羊角的生物。在某些传说中,它拥有模仿人类声音的天赋。但并非所有长角的兔子都是虚构的。1931年,洛克菲勒研究所的研究员理查德·肖普注意到,他在新泽西州普林斯顿附近射杀的一只兔子脚上长有肿瘤;不久后,他开始收集并研究其他野兔身上的类似肿瘤。一天,肖普实验室一位管理员的父亲从爱荷华州切罗基来访,他说这些肿瘤与他家乡所见相比根本不值一提。“他说他曾射杀过长角的兔子,那些角从头部两侧长出,像得克萨斯公牛一样,或是从鼻子上方冒出,如同犀牛角,”肖普在未发表的笔记中写道。肖普随这位爱荷华州人前往当地数日,猎捕长角的棉尾兔;临行前,他留下五美元和一瓶甘油,并承诺会为任何寄给他的兔角再支付五美元。

Shope was a physician’s son, also from Iowa, who lost friends to the 1918 influenza epidemic—he went on to study the influenza virus. He had studied swine flu, as well; his swine-flu co-researcher died from a viral disease he was researching. From the growths on the cottontails—whose cause might plausibly have been genetic, environmental, or infectious—Shope isolated a previously unknown virus, a rabbit papillomavirus. Some of the growths turned into cancers, and, in his 1933 paper “Infectious Papillomatosis of Rabbits,” he demonstrated the first known example of a virus in a mammal causing cancer. He also developed a vaccine against the virus, which proved especially useful when a French bacteriologist thought to control the rabbit population on his property by importing two infected rabbits—which led within a year to the loss of approximately half the wild rabbits in France.

肖普也是一位医生的儿子,同样来自爱荷华州,他的朋友在1918年流感大流行中丧生——这促使他后来致力于研究流感病毒。他还研究过猪流感;与他共同研究猪流感的同事死于自己正在研究的病毒性疾病。从棉尾兔身上的增生组织(其成因可能涉及遗传、环境或感染因素)中,肖普分离出一种此前未知的病毒——兔乳头瘤病毒。部分增生组织最终癌变,他在1933年发表的论文《兔传染性乳头状瘤病》中,首次证明了病毒在哺乳动物体内引发癌症的实例。他还研制出针对该病毒的疫苗,这项成果后来发挥了重要作用:一位法国细菌学家曾试图通过引进两只感染病毒的兔子来控制自家土地上的兔群数量,结果一年内导致法国近半数野生兔子死亡。

Hundreds of papillomaviruses have been documented in other mammals, such as humans. “My first job was in a gynecological-pathology rotation,” Margaret Stanley, an emeritus professor of epithelial biology at the University of Cambridge, told me. It was 1967, and she spent her time reading cervical Pap smears, which are used to detect cancerous or precancerous cells. “Cervical cancer was fascinating, because it quite obviously had an infectious cause,” she said. “But nobody could find out what the pathogen was.” By the mid-eighties, a team led by the German virologist Harald zur Hausen demonstrated that a human-papillomavirus infection was the main cause of most cervical cancers. (There are more than two hundred known human papillomaviruses, fourteen of which are known to potentially cause cancer.) This meant that preventing H.P.V. infection would mean preventing nearly all cervical cancers. The search for a vaccine was on.

在其他哺乳动物中,已发现数百种乳头瘤病毒,人类也不例外。“我的第一份工作是在妇科病理科轮转,”剑桥大学上皮生物学荣休教授玛格丽特·斯坦利告诉我。那是1967年,她整日埋头于检测宫颈癌或癌前病变的宫颈涂片。“宫颈癌非常奇特,因为它显然具有传染性病因,”她说,“但当时无人能确定病原体究竟是什么。”到八十年代中期,德国病毒学家哈拉尔德·楚尔·豪森领导的团队证实,人类乳头瘤病毒感染是绝大多数宫颈癌的主要诱因。(目前已知人类乳头瘤病毒超过两百种,其中十四种可能致癌。)这意味着预防HPV感染就能预防几乎所有宫颈癌。一场疫苗研发的征程就此开启。

Viruses, broadly speaking, are like zombies. They have none of the complex inner life of, say, bacteria, with their cytoplasm and their protein-making ribosomes. And viruses are generally not classed as “living”—an unstable classification, still under debate—because they cannot reproduce on their own. Instead, a virus sneaks into a living cell and takes over its systems of production, so that the infected cell’s factory replicates the virus’s genetic material rather than its own. Without a host cell, a virus is little more than scraps of genetic material waiting for a break.

从广义上说,病毒就像僵尸。它们不像细菌那样拥有复杂的内部生命,比如细胞质和制造蛋白质的核糖体。而且病毒通常不被归类为“生物”——这是一个不稳定的分类,至今仍有争议——因为它们无法自行繁殖。相反,病毒会潜入活细胞并接管其生产系统,使受感染细胞的工厂复制病毒的遗传物质,而不是自身的遗传物质。没有宿主细胞,病毒不过是一堆等待机会的遗传物质碎片。

The body’s defenses can often mount an effective attack on a virus, as long as the immune system “notices” it. Stanley wanted to understand why the body doesn’t tend to clear H.P.V., as it does so many other viral infections. She came to understand that what’s so clever about human papillomaviruses is that, in a sense, they’re not much trouble. H.P.V. infects epithelial cells, the outermost layer of cells—and doesn’t proceed much beyond there. Stanley explained, “Epithelial cells go through their life cycle. They’re born. They mature. They die. And they get sloughed off.” The fully formed virus particles, there in the sloughed-off cells, go on to infect other living epithelial cells. “It doesn’t need to kill a cell,” Stanley said. “The cell is going to die anyway. It’s a very efficient life cycle.” In this way, H.P.V.’s viral particles are unobtrusive. But then, sometimes, they cause the epithelial cells to become cancerous.

人体的防御系统通常能对病毒发起有效攻击,只要免疫系统“注意到”它。斯坦利想了解为什么人体往往无法像清除许多其他病毒感染那样清除HPV。她逐渐认识到,人乳头瘤病毒的巧妙之处在于,从某种意义上说,它们并不制造太多麻烦。HPV感染上皮细胞,即最外层的细胞——并且很少超出这个范围。斯坦利解释说:“上皮细胞经历它们的生命周期。它们诞生、成熟、死亡,然后脱落。”在脱落的细胞中,完全形成的病毒颗粒继续感染其他活的上皮细胞。“它不需要杀死细胞,”斯坦利说,“细胞反正会死亡。这是一个非常高效的生命周期。”通过这种方式,HPV的病毒颗粒显得不引人注目。但有时,它们会导致上皮细胞癌变。

Developing an H.P.V. vaccine was distinctly challenging. One reason was that cancers from H.P.V. usually occur many years after the initial infection. A vaccine trial might need to run for decades, and such a delay could be life-costing, as well as impractical.

研发HPV疫苗面临着独特的挑战。其中一个原因是,HPV引发的癌症通常在初次感染多年后才显现。疫苗试验可能需要持续数十年,这种漫长的等待不仅不切实际,更可能以生命为代价。

The epidemiologist Laura Koutsky, of the University of Washington, got around this problem by designing, with others, a double-blind study in which more than two thousand women were given three doses of the vaccine or an equivalent placebo and then screened every six months—not for cancer but, instead, simply for H.P.V.-16 infection. (H.P.V.-16 is the most common cancer-causing strain.) An early report, published a bit more than a year later, showed no H.P.V.-16 infections in the vaccinated group. Even ten years later, the women who had been immunized remained protected. “It was absolutely stunning,” Stanley said. In terms of extending life, getting an H.P.V. vaccine is as important for a woman as quitting smoking.

华盛顿大学的流行病学家劳拉·考茨基与他人共同设计了一项双盲研究,成功解决了这一难题。该研究为两千多名女性接种了三剂疫苗或同等剂量的安慰剂,随后每半年进行一次筛查——筛查目标并非癌症本身,而是单纯检测HPV-16病毒感染(HPV-16是最常见的致癌亚型)。一年后发布的早期报告显示,疫苗接种组未出现HPV-16感染病例。即便十年后,接种疫苗的女性仍具有免疫力。“这简直令人震撼,”斯坦利评价道。就延长寿命而言,女性接种HPV疫苗的重要性堪比戒烟。

Ruanne Barnabas, a physician-scientist, grew up in South Africa, where her father worked as a botanist and her mother was a public-health doctor. “They weren’t maybe as organized as they could have been, so I would go to the hospital with my mom on the weekends,” she said. She also spent many afternoons in her dad’s laboratory, drawing botanical specimens. Her medical training, which coincided with the beginning of the AIDS epidemic, focussed on infectious disease, and she later continued her training with a Ph.D. in medicine and clinical epidemiology at Oxford. For her thesis, she constructed mathematical models using clinical trials of the first H.P.V. vaccines approved for use in England and in the U.S. The vaccine was capable of saving lives—the pressing question was how to increase access and lower costs. Cervical cancer is currently the fourth most common cancer in women globally, but in countries such as India and Kenya its prevalence is second only to breast cancer. Although the cost of H.P.V. vaccines is within reach for well-off countries, it is a stretch for most low- and middle-income ones.

鲁安妮·巴纳巴斯是一名医生兼科学家,她在南非长大,父亲是植物学家,母亲是公共卫生医生。“他们可能没有像他们本可以做到的那样有条理,所以我周末会和我妈妈一起去医院,”她说。她还在父亲的实验室里度过了许多个下午,绘制植物标本。她的医学培训恰逢艾滋病开始流行,专注于传染病,后来她在牛津大学继续深造,获得了医学和临床流行病学博士学位。在她的论文中,她利用首批在英国和美国获批使用的HPV疫苗的临床试验数据构建了数学模型。这种疫苗能够拯救生命——紧迫的问题是如何提高可及性并降低成本。宫颈癌目前是全球女性第四大常见癌症,但在印度和肯尼亚等国家,其患病率仅次于乳腺癌。尽管HPV疫苗的成本对于富裕国家来说是可以承受的,但对于大多数中低收入国家来说却是一笔不小的开支。

It seemed pretty clear initially that H.P.V. vaccines would require a three-dose regimen. They are made of virus-like particles, rather than parts of the virus itself, and such vaccines (called protein-based vaccines) generally provoke only a weak immune response after the first dose. The follow-up doses boost that response. But getting people to turn up three times is an iffy proposition. This difficulty is amplified not only by ambient vaccine skepticism but also by the fact that H.P.V. is sexually transmitted and vaccines against it are ideally given to girls and young women. In Japan, in 2013, unfounded reports of the H.P.V. vaccine causing chronic pain or other neurological side effects spread in the media, leading the government temporarily to suspend its H.P.V. recommendation. Vaccination rates fell from seventy per cent to less than one per cent. In 2014, in northern Colombia, hundreds of school-age girls who had received the H.P.V. vaccine went to medical centers complaining of a racing heart, shortness of breath, and numbness in their arms and legs; a medical investigation concluded that the vaccines were not the cause, but the conclusion was poorly received.

起初,HPV疫苗似乎明确需要接种三剂。这类疫苗由病毒样颗粒而非病毒本身的部分制成,属于蛋白疫苗,通常首剂仅能引发较弱的免疫反应,后续剂次则能增强该反应。然而,让民众完成三次接种存在不确定性。这一困难不仅因普遍的疫苗怀疑论而加剧,还因HPV通过性传播,其疫苗的理想接种对象是女孩和年轻女性。2013年,日本媒体传播了HPV疫苗可能导致慢性疼痛或其他神经系统副作用的无根据报道,导致政府暂时中止了对HPV疫苗的推荐,接种率从70%骤降至不足1%。2014年,哥伦比亚北部数百名接种过HPV疫苗的学龄女孩因心悸、呼吸急促及四肢麻木前往医疗中心就诊;医学调查认定疫苗并非病因,但这一结论并未被广泛接受。

In an H.P.V. vaccine trial that began in 2004 in Costa Rica, one of the most important findings came about by the by. Some seventy-five hundred women between the ages of eighteen and twenty-five were enrolled. However, for various reasons, pregnancy being a major one, about twenty per cent of them received fewer than three doses. But even the women who received only one developed antibody levels nine times higher than those found in naturally infected individuals. The vaccine efficacy among the groups remained essentially equal, even years down the line. Aimée Kreimer, the lead author on this discovery, suggested that maybe one dose was sufficient. “Kreimer was subjected to God knows how much skepticism,” Stanley, who counted herself among the disbelievers back then, said. “It was heresy for a protein-based vaccine to work with only one dose.”

在一项始于2004年的哥斯达黎加HPV疫苗试验中,最重要的发现竟出自偶然。约七千五百名18至25岁的女性参与了这项研究。然而,由于各种原因(怀孕是主要因素),约20%的参与者接种剂次少于三针。但即便是仅接种一针的女性,其抗体水平也达到了自然感染者的九倍之高。多年后数据显示,各组的疫苗保护效果基本持平。这项发现的主要作者艾梅·克莱默由此提出单剂接种可能已足够。“天知道克莱默承受了多少质疑,”斯坦利回忆道,她坦言自己当时也是质疑者之一,“对于蛋白疫苗而言,单剂有效简直是异端邪说。”

Then a trial in India, begun in 2009, went even more wrong. The trial was looking at the efficacy of going from three H.P.V. doses to two. Led by the International Agency for Research Against Cancer, the trial enrolled twenty thousand girls and women. Before several months had passed, seven girls in a different H.P.V.-vaccine study—a demonstration study led by the nonprofit Program for Appropriate Technology in Health—died, and both the I.A.R.C. and PATH trials were stopped. (An investigation uncovered that one girl had drowned, another died from snake bite, two had swallowed poisonous pesticides, one died as a result of malaria, another of what was suspected to be a cerebral hemorrhage, and one of a high fever that Indian government investigators concluded was “very unlikely” to have resulted from the vaccine.) Some women had received one dose, and some two or three, but the women with one dose appeared to be as protected as those with more.

随后,印度于2009年启动的一项试验更是错上加错。该试验旨在研究HPV疫苗从三剂改为两剂的效果。这项由国际癌症研究机构主导的试验招募了两万名女孩和妇女。然而不到几个月,另一项由非营利组织适宜卫生科技组织主导的HPV疫苗示范研究中,有七名女孩死亡,导致国际癌症研究机构和适宜卫生科技组织的两项试验均被叫停。(后续调查显示:一名女孩溺水身亡,一名死于蛇咬,两人吞服有毒农药,一人因疟疾死亡,另一人疑似脑出血,还有一人发高烧去世——印度政府调查人员认定其死因“极不可能”与疫苗有关。)部分女性接种了一剂疫苗,部分接种了两到三剂,但仅接种一剂的女性似乎与接种多剂的女性获得了同等保护。

Still, reasonable skepticism of a one-dose approach remained, so Barnabas and an extensive team conducted a clinical trial, the KEN SHE study, in Kenya, which was about to become a lower-middle-income country, cutting it off from its international vaccine subsidies and pushing it to find cheaper solutions. Young women enrolled in the trial received either an H.P.V. vaccine or a meningococcal vaccine. “And at eighteen months we found very high efficacy for a single dose,” Barnabas said. Even after more than four years of follow-up, single-dose vaccination continued to show an efficacy of more than ninety-eight per cent. I asked Barnabas if she encountered much resistance to H.P.V. vaccines during the study. “In Kenya, if you ask people, ‘Does anyone know someone who’s been affected by cervical cancer?,’ half the hands in the room go up,” she said. The cancer is often diagnosed late in Kenya, and mortality is around fifty per cent. “It’s so disruptive to communities and families to lose women in the middle of their adult lives,” Barnabas added. In December, 2025, Kreimer was the lead author of a New England Journal of Medicine publication of the results of another trial in Costa Rica, the ESCUDDO trial: a controlled, randomized, double-blinded study with some twenty thousand participants that found that one dose of an H.P.V. vaccine was not inferior to two.

然而,对单剂接种方案的合理质疑依然存在,因此巴纳巴斯与一个庞大的团队在肯尼亚开展了一项名为“KEN SHE”的临床试验。当时的肯尼亚即将迈入中低收入国家行列,这意味着它将失去国际疫苗补贴,不得不寻求更经济的解决方案。参与试验的年轻女性分别接种了HPV疫苗或脑膜炎球菌疫苗。“18个月后我们发现单剂疫苗具有极高有效性,”巴纳巴斯说。即使在超过四年的随访期后,单剂疫苗接种仍保持超过98%的有效率。当我询问巴纳巴斯在研究过程中是否遭遇对HPV疫苗的强烈抵制时,她表示:“在肯尼亚,如果你问'有人认识宫颈癌患者吗?',房间里会有一半人举手。”这种癌症在肯尼亚往往确诊较晚,死亡率约为50%。“女性在中年时期离世对社区和家庭造成的冲击是毁灭性的,”巴纳巴斯补充道。2025年12月,克雷默作为第一作者在《新英格兰医学杂志》发表了哥斯达黎加ESCUDDO试验的结果:这项涉及约两万名参与者的对照随机双盲研究表明,单剂HPV疫苗的效果不逊于双剂接种。

Some ninety countries now follow a single-dose regimen. Although the U.S. has been relatively late to make the switch, it will benefit in ways beyond the cost savings. Already, many Americans, for various reasons, receive only one dose. A close friend of mine had both of her children receive the first dose; she then came under enormous pressure from both her mother and her mother-in-law not to let them get further shots—they thought the vaccines were dangerous. My friend felt overwhelmed by the ongoing emotional pleas made by the respected older women in her life, and she didn’t send her kids in for doses two and three. “I’ve always said, the U.S. has in effect for years been a one-dose country,” Stanley told me. When my friend heard that one dose was sufficient, she was relieved. Then, not long afterward, her mother-in-law reached out to say that she had just learned that there was a vaccine that could prevent cancer, that she had never heard of such a thing, and that the kids should go and get it straight away. ♦

目前约有九十个国家采用单剂接种方案。尽管美国在转向单剂方案上相对滞后,但此举带来的益处远不止于成本节约。实际上,许多美国人因各种原因早已只接种一剂疫苗。我的一位挚友让她的两个孩子接种了第一剂疫苗后,便承受过来自母亲和婆婆的巨大压力——两位长辈认为疫苗危险,坚决反对孩子继续接种。面对生命中两位德高望重的长辈持续的情感攻势,我的朋友最终妥协,没有让孩子接种第二剂和第三剂疫苗。“我一直认为,美国实质上早已是个单剂接种国家。”斯坦利告诉我。当我的朋友得知单剂接种已足够时,如释重负。而不久后,她的婆婆又主动联系说,刚听说有种疫苗可以预防癌症,自己从未听闻如此神奇之物,催促孩子们应当立即去接种。♦

2 free previews left — register to get 30 translations a month